Neutrophil gelatinase-associated lipocalin: Ready for routine clinical use? An international perspective

Blood Purification

Volumn 37, Issue 4, 2014, Pages 271-285

  Ronco, Claudio ^a   Legrand, Matthieu ^d   Goldstein, Stuart L ^e   Hur, Mina ^h   Tran, Nam ^f   Howell, Eric C ^f   Cantaluppi, Vincenzo ^b   Cruz, Dinna N ^g   Damman, Kevin ⁱ   Bagshaw, Sean M ^j   Somma, Salvatore Di ^c   Lewington, Andrew ^k  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Konkuk University School of Medicine   (South Korea)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j UNIVERSITY OF ALBERTA   (Canada)

^k ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

Acute kidney injury; Chronic kidney disease; Neutrophil gelatinase associated lipocalin

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCINEURIN INHIBITOR; CREATININE; CYSTATIN C; FENOLDOPAM; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ABDOMINAL COMPARTMENT SYNDROME; ACUTE KIDNEY FAILURE; BODY SURFACE; BURN; BURN PATIENT; BURN SHOCK; CARDIOPULMONARY BYPASS; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMPARTMENT SYNDROME; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DELAYED GRAFT FUNCTION; EMERGENCY WARD; ENDOTOXEMIA; EXTENDED CRITERIA DONOR; FLUID RESUSCITATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERVOLEMIA; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIMB COMPARTMENT SYNDROME; NEPHROTOXICITY; NONHUMAN; POINT OF CARE TESTING; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; URINE VOLUME; ACUTE KIDNEY INJURY; AGE; BLOOD; BURNS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); CRITICAL ILLNESS; GRAFT SURVIVAL; MORTALITY; RENAL REPLACEMENT THERAPY; RESUSCITATION; TREATMENT OUTCOME; URINE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; AGE FACTORS; BIOLOGICAL MARKERS; BURNS; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; GRAFT SURVIVAL; HUMANS; INTENSIVE CARE UNITS; LIPOCALINS; NATRIURETIC PEPTIDE, BRAIN; PROTO-ONCOGENE PROTEINS; RENAL REPLACEMENT THERAPY; RESUSCITATION; SEPSIS; TREATMENT OUTCOME;

EID: 84903859073     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000360689     Document Type: Review

References (59)

1. Legrand M: NGAL: A biomarker of injury, not function. Presentation in A. Lewington (Chair), NGAL: Ready for Routine Clinical Use? An International Perspective. Symposium at 31st International Vicenza Course on Critical Care Nephrology, Vicenza, 2013.
2. Lameire NH, Vanholder RC, Van Biesen WA: How to use biomarkers efficiently in acute kidney injury. Kidney Int 2011; 79: 1047-1050.
3. Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W: Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant 2013; 28: 254-273.
4. Legrand M, Collet C, Gayat E, Henao J, Giraudeaux V, Mateo J, Launay JM, Payen D: Accuracy of urine NGAL commercial assays in critically ill patients. Intensive Care Med 2013; 39: 541-542.
5. Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM, Viltard M, Yu W, Forster CS, Gong G, Liu Y, Kulkarni R, Mori K, Kalandadze A, Ratner AJ, Devarajan P, Landry DW, D'Agati V, Lin CS, Barasch J: The NGAL reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011; 17: 216-222.
6. Goldstein SL: Using NGAL to direct care in pediatric research. Presentation in A. Lewington (Chair), NGAL: Ready for Routine Clinical Use? An International Perspective. Symposium at 31st International Vicenza Course on Critical Care Nephrology, Vicenza, 2013.
7. Goldstein SL: Use of biomarkers to optimize fluid dosing, CRRT initiation and discontinuation in pediatric ICU patients with AKI. Current Controlled Trials. 2012. http://clinicaltrials. gov/ct2/show/NCT01416298.
8. Sutherland SM, Zappitelli M, Alexander SR, Chua AN, Brophy PD, Bunchman TE, Hackbarth R, Somers MJ, Baum M, Symons JM, Flores FX, Benfield M, Askenazi D, Chand D, Fortenberry JD, Mahan JD, McBryde K, Blowey D, Goldstein SL: Fluid overload and mortality in children receiving continuous renal replacement therapy: The Prospective Pediatric Continuous Renal Replacement Therapy Registry. Am J Kidney Dis 2010; 55: 316-325.
9. Ricci Z, Luciano R, Favia I, Garisto C, Muraca M, Morelli S, Di Chiara L, Cogo P, Picardo S: High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery. Crit Care 2011; 15:R160.
10. Hur M: Plasma neurophil gelatinase-associated lipocalin as a biomarker for acute kidney injury in critically ill patients with suspected sepsis. Presentation in A. Lewington (Chair), NGAL: Ready for Routine Clinical Use? An International Perspective. Symposium at 31st International Vicenza Course on Critical Care Nephrology, Vicenza, 2013.
11. Kim H, Hur M, Cruz DN, Moon HW, Yun YM: Plasma neutrophil gelatinase-associated lipocalin as a biomarker for acute kidney injury in critically ill patients with suspected sepsis. Clin Biochem 2013; 46: 1414-1418.
12. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
13. Koyner JL, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhter SA, Raman J, Jeevanandam V, O'Connor MF, Devarajan P, Bonventre JV, Murray PT: Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 2010; 5: 2154-2165.
14. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-518.
15. Tang BM, Eslick GD, Craig JC, McLean AS: Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 210-217.
16. Hur M, Moon HW, Yun YM, Kim KH, Kim HS, Lee KM: Comparison of diagnostic utility between procalcitonin and C-reactive protein for the patients with blood culture-positive sepsis (in Korean). Korean J Lab Med 2009; 29: 529-535.
17. Tran N, Howell EC: BNP and NGAL for acute resuscitation in severely burned patients. Presentation in A. Lewington (Chair), NGAL: Ready for Routine Clinical Use? An International Perspective. Symposium at 31st International Vicenza Course on Critical Care Nephrology, Vicenza, 2013.
18. Mosier MJ, Pham TN, Klein MB, Gibran NS, Arnoldo BD, Gamelli RL, Tompkins RG, Herndon DN: Early acute kidney injury predicts progressive renal dysfunction and higher mortality in severely burned adults. J Burn Care Res 2010; 31: 83-92.
19. Baxter C, Shires T: Physiologic response to crystalloid resuscitation in severe burns. Ann NY Acad Sci 1968; 150: 874-893.
20. Friese RS, Dineen S, Jennings A, Pruitt J, Mc- Bride D, Shafi S, Frankel H, Gentilello LM: Serum B-type natriuretic peptide: a marker of fluid resuscitation after injury? J Trauma 2007; 62: 1346-1350.
21. Devarajan P: Review: Neutrophil gelatinaseassociated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology 2010; 15: 419-428.
22. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.
23. Cantaluppi V: Plasma NGAL is an early biomarker of delayed graft function and CNI nephrotoxicity in kidney transplantation from extended criteria donors. Presentation in A. Lewington (Chair), NGAL: Ready for Routine Clinical Use? An International Perspective. Symposium at 31st International Vicenza Course on Critical Care Nephrology, Vicenza, 2013.
24. Wolfe RA, Vashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
25. Arns W, Citterio F, Campistol JM: 'Old-forold' - new strategies for renal transplantation. Nephrol Dial Transplant 2007; 22: 336-341.
26. Quiroga I, McShane P, Koo DDH, Gray D, Friend PJ, Fuggle S, Darby C: Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006; 21: 1689-1696.
27. Halloran PF: T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transplant 2010; 10: 1126-1134.
28. Siedlecki A, Irish W, Brennan DC: Delayed graft function in the kidney transplant. Am J Transplant 2011; 11: 2279-2296.
29. Hall IE, Yarlagadda SG, Coca SG, et al: Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ, Parikh CR: IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 2010; 21: 189-197.
30. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Berger T, Mak TW, Knebelmann B, Friedlander G, Barasch J, Terzi F: Lipocalin-2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 2010; 120: 4065-4076.
31. Cruz DN: Beyond the kidneys: NGAL as a biomarker of cardiovascular disease. Presentation in A. Lewington (Chair), NGAL: Ready for Routine Clinical Use? An International Perspective. Symposium at 31st International Vicenza Course on Critical Care Nephrology, Vicenza, 2013.
32. Hemdahl A-L, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thorén P, Hansson GK: Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006; 26: 136-142.
33. Folkesson M, Kazi M, Zhu C, Silveira A, Hemdahl AL, Hamsten A, Hedin U, Swedenborg J, Eriksson P: Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb Haemost 2007; 98: 427-433.
34. Cruz DN, Gaiao S, Maisel A, Ronco C, Devarajan P: Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review. Clin Chem Lab Med 2012; 50: 1533-1545.
35. Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, Clopton P, van Veldhuisen DJ: Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011; 13: 846-851.
36. Nymo S H, Ueland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, Wikstrand J, McMurray J, Van Veldhuisen DJ, Gullestad L, Aukrust P, Yndestad A: The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA. J Intern Med 2011; 271: 436-443.
37. Daniels LB, Barrett-Connor E, Clopton P, Laughlin GA, Ix JH, Maisel AS: Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study. J Am Coll Cardiol 2012: 59: 1101-1109.
38. Damman K: NGAL in heart failure. Presentation in Al Lewington (Chair), NGAL: Ready for Routine Clinical Use? An International Perspective. Symposium at 31st International Vicenza Course on Critical Care Nephrology, Vicenza, 2013.
39. Hillege HL, Girbes ARJ, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210.
40. Entin-Meer M, Ben-Shoshan J, Maysel-Auslender S, Levy R, Goryainov P, Schwartz I, Barshack I, Avivi C, Sharir R, Keren G: Accelerated renal fibrosis in cardiorenal syndrome is associated with long-term increase in urine neutrophil gelatinase-associated lipocalin levels. Am J Nephrol 2012; 36: 190-200.
41. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL: Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 997-1000.
42. Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL: Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010; 96: 1297-1302.
43. Alvelos M, Lourenço P, Dias C, Amorim M, Rema J, Leite AB, Guimarães JT, Almeida P, Bettencourt P: Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol 2013; 165: 51-55.
44. Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, van Veldhuisen DJ, Montagna L, Cosmi F, Tognoni G, Tavazzi L, Latini R: Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011; 32: 2705-2712.
45. Tavazzi L, Tognoni G: GISSI-HF: effects of n-3 PUFA and rosuvastatin on mortalitymorbidity of patients with symptomatic CHF. Current Controlled Trials. 2006. http://clinicaltrials. gov/ct2/show/NCT00336336.
46. Collins SP, Hart KW, Lindsell CJ, Fermann GJ, Weintraub NL, Miller KF, Roll SN, Sperling MI, Sawyer DB, Storrow AB: Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail 2012; 14: 1020-1029.
47. Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH: Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 2010; 16: 49-54.
48. Breidthardt T, Socrates T, Drexler B, Noveanu M, Heinisch C, Arenja N, Klima T, Züsli C, Reichlin T, Potocki M, Twerenbold R, Steiger J, Mueller C: Plasma neutrophil gelatinase- associated lipocalin for the prediction of acute kidney injury in acute heart failure. Crit Care 2012; 16:R2.
49. Maisel A, Murray P: Acute kidney injury neutrophil gelatinase-associated lipocalin (NGAL) evaluation of symptomatic heart failure study (AKINESIS). Current Controlled Trials. 2011. http://clinicaltrials.gov/ct2/show/ NCT01291836.
50. Bagshaw SM: NGAL and renal replacement therapy in the ICU. Presentation in A. Lewington (Chair), NGAL: Ready for Routine Clinical Use? An International Perspective. Symposium at 31st International Vicenza Course on Critical Care Nephrology, Vicenza, 2013.
51. Bagshaw SM, Bennett M, Haase M, Haase- Fielitz A, Egi M, Morimatsu H, d'Amico G, Goldsmith D, Devarajan P, Bellomo R: Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med 2010; 36: 452-461.
52. Koyner JL, Garg AX, Coca SG, Sint K, Thiessen- Philbrook H, Patel UD, Shlipak MG, Parikh CR; TRIBE-AKI Consortium: Biomarkers predict progression of acute kidney injury after cardiac surgery. J Am Soc Nephrol 2012; 23: 905-914.
53. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A; NGAL Meta-Analysis Investigator Group: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54: 1012-1024.
54. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, Buchen C, Khan F, Mori K, Giglio J, Devarajan P, Barasch J: Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008; 148: 810-819.
55. Basu RK, Chawla LS, Wheeler DS, Goldstein SL: Renal angina: an emerging paradigm to identify children at risk for acute kidney injury. Pediatr Nephrol 2012; 27: 1067-1078.
56. Goldstein SL, Chawla LS: Renal angina. Clin J Am Soc Nephrol 2010; 5: 943-949.
57. Di Somma S: NGAL use and experiences for AKI detection in the emergency department. Presentation in A. Lewington (Chair), NGAL: Ready for Routine Clinical Use? An International Perspective. Symposium at 31st International Vicenza Course on Critical Care Nephrology, Vicenza, 2013.
58. Di Somma S, Magrini L, De Berardinis B, Marino R, Ferri E, Moscatelli P, Ballarino P, Carpinteri G, Noto P, Gliozzo B, Paladino L, Di Stasio E: Additive value of blood neutrophil gelatinase-associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department. Crit Care 2013; 17:R29.
59. Kellermann AL: Crisis in the emergency department. N Engl J Med 2006; 355: 1300-1303.